ProfileGDS5678 / 1455829_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 77% 76% 77% 80% 77% 78% 78% 78% 77% 78% 78% 77% 77% 79% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.2379777
GSM967853U87-EV human glioblastoma xenograft - Control 25.1769976
GSM967854U87-EV human glioblastoma xenograft - Control 35.202577
GSM967855U87-EV human glioblastoma xenograft - Control 45.7919380
GSM967856U87-EV human glioblastoma xenograft - Control 55.2488777
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.26778
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.2139478
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.3088578
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.2867777
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.4737878
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.3194678
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.2140677
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.1949677
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.5144679